PULSION Medical Systems SE announced group financial results for the second quarter and six months ended June 30, 2013. For the quarter, the company reported sales of €9.080 million against €8.914 million a year ago. Profit before interest and taxes (EBIT) was €2.057 million against €2.918 million a year ago. EBITDA was €2.546 million against €3.460 million a year ago. Group net profit was €2.326 million or €0.28 per diluted share against €2.116 million or €0.24 per diluted share a year ago. Cash flow from operating activities before changes in net working capital was €2.086 million against €2.927 million a year ago. Cash flow from operating activities after changes in net working capital was €3.199 million against €5.060 million a year ago. Operating profit was €2.255 million against €2.878 million a year ago. Purchase of intangible assets was €0.348 million against €0.002 million a year ago. Purchase of property, plant and equipment (incl. monitors) was €0.189 million against €0.400 million a year ago.

For the six months, the company reported sales of €18.534 million against €17.269 million a year ago. Profit before interest and taxes (EBIT) was €4.807 million against €4.793 million a year ago. EBITDA was €5.722 million against €5.789 million a year ago. Group net profit was €4.164 million or €0.51 per diluted share against €3.617 million or €0.24 per diluted share a year ago. Cash flow from operating activities before changes in net working capital was €1.332 million against €3.376 million a year ago. Cash flow from operating activities after changes in net working capital was €2.368 million against €5.713 million a year ago. Operating profit was €4.977 million against €4.752 million a year ago. Purchase of intangible assets was €0.522 million against €0.013 million a year ago. Purchase of property, plant and equipment (incl. monitors) was €0.512 million against €0.716 million a year ago.

For the full financial year 2013 the company is targeting sales growth of at least 6 %, which would entail a slight acceleration in the growth rate compared to the previous year. After the actual results for the first quarter 2013 became known, a target-EBIT corridor of 24 % to 28 % was announced as guidance for the full year 2013; it considers that this guidance remains realistic. Earnings per share are expected to be within a range of €0.95 to €1.05, approximately 20 % higher than the previous year's figure of €0.82.